Rapid onset type 1 diabetes with anti-PD-1 directed therapy

Type 1 diabetes is a rare immune-related adverse event (irAE) caused by checkpoint inhibitors with serious risk for diabetic ketoacidosis (DKA). Using our electronic medical record, we identified 1327 adult patients who received PD-(L)1 or CTLA-4 inhibitors from 2013 to 2018. Of the patients who rec...

Descripción completa

Detalles Bibliográficos
Autores principales: Yun, Karen, Daniels, Gregory, Gold, Kathryn, Mccowen, Karen, Patel, Sandip Pravin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7367652/
https://www.ncbi.nlm.nih.gov/pubmed/32733645
http://dx.doi.org/10.18632/oncotarget.27665

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7367652/
https://www.ncbi.nlm.nih.gov/pubmed/32733645
http://dx.doi.org/10.18632/oncotarget.27665

Ejemplares similares